Chronic dry eye disease is characterized by persistent symptoms and a high risk of recurrence—particularly during seasonal transitions, after sleep deprivation, or following prolonged visual tasks. Many patients experience temporary relief with acute-phase treatments but struggle with symptom rebound once therapy is discontinued. This cycle of intermittent treatment and relapse underscores a critical unmet need: effective, long-term maintenance strategies that address the underlying pathophysiology rather than merely alleviating surface-level discomfort.
For patients navigating recurrent dry eye, the question “What eye drop should I use for sustained control?” is both practical and clinically significant. Emerging evidence and updated clinical guidelines point to low-concentration cyclosporine ophthalmic solution—specifically Zirun Cyclosporine Eye Drops (II)—as a preferred option for the consolidation phase of management.
1. Targeting the root cause: chronic ocular surface inflammation
Recurrence in dry eye is strongly linked to unresolved subclinical inflammation on the ocular surface. The 2024 Chinese Expert Consensus on Clinical Diagnosis and Treatment of Dry Eye emphasizes that low-dose cyclosporine A exerts selective immunomodulatory effects by inhibiting T-lymphocyte activation and suppressing pro-inflammatory cytokine release—including IL-2, TNF-α, and IFN-γ. When used during the consolidation phase, it helps sustain immune homeostasis at the ocular surface, thereby reducing the likelihood of inflammatory reactivation triggered by environmental or behavioral stressors.
2. Restoring endogenous tear function
Zirun Cyclosporine Eye Drops (II) have demonstrated efficacy in enhancing lacrimal gland secretory function and upregulating mucin production—key components of a healthy, stable tear film. By improving intrinsic tear quality and volume, the therapy raises the threshold for symptom onset. Patients report greater resilience against common triggers such as digital screen exposure or circadian disruption, translating into longer intervals between flares and improved quality of life.
3. Favorable safety profile for extended use
Unlike short-term corticosteroid regimens—which carry risks of intraocular pressure elevation and cataract formation—low-concentration cyclosporine (0.05%) is well tolerated over prolonged periods. Notably, Zirun Cyclosporine Eye Drops (II) are preservative-free, eliminating potential toxicity from benzalkonium chloride or other antimicrobial agents commonly found in multi-dose formulations. This makes it particularly suitable for maintenance therapy, supporting continuous anti-inflammatory action without compromising epithelial integrity.
The 2026 *Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach* formally designate 0.05% cyclosporine ophthalmic solution as a first-line therapeutic agent for moderate-to-severe dry eye, especially in cases requiring long-term disease modulation. Its dual mechanism—suppressing inflammation while promoting glandular recovery—positions it uniquely to foster a more resilient ocular surface microenvironment.
Clinical considerations for consolidation therapy
Patients should be counseled that symptom resolution does not equate to disease quiescence. Premature discontinuation—even after apparent improvement—can precipitate inflammatory rebound and increase recurrence risk. Current recommendations support continuing therapy for one to two additional treatment cycles post-symptom resolution before tapering under specialist supervision.
Self-adjustment of dosing—such as increasing frequency or concentration upon recurrence—is strongly discouraged. Recurrent symptoms warrant clinical reassessment to determine whether inflammation has reactivated, whether comorbidities (e.g., meibomian gland dysfunction or systemic autoimmune conditions) require concurrent management, or whether alternative therapeutic strategies are indicated.
Complementary lifestyle measures remain essential
Maintenance pharmacotherapy works best alongside non-pharmacologic interventions: consistent blink training during screen use, humidification in dry environments, avoidance of dietary irritants (e.g., excessive spicy or processed foods), and prioritization of sleep hygiene and systemic immune health. These measures synergize with cyclosporine’s immunomodulatory effects to further stabilize the ocular surface.